Weak Q4 results and MS portfolio should be cause for concern for Biogen, says GlobalData
Following Biogen’s Q4 and full year 2018 earnings call (29 January), Antoine Grey, Pharma Analyst at GlobalData, a leading data and analytics company, offers his vie...




